News

Donnerstag, 16.02.2023

Habilitation of PD Dr. rer. nat. Stephanie Goletz

We congratulate PD Dr. rer. nat. Stephanie Goletz, who completed her habilitation at the University of Lübeck in the field of Experimental Dermatology
with her inaugural lecture "Fast and easy - Verbesserte Diagnostik bullöser Autoimmundermatosen" on 31 January!

Mittwoch, 09.02.2022

Study guide and review Diseases of the Oral Mucosa

 Schmidt E. (Ed.), Springer, 2021 | https://link.springer.com/978-3-030-82804-2
 

  • Details the latest diagnosis and management options...

Montag, 01.11.2021

Comprehensive review article on "Lichen planus" published

 Boch et al, Lichen planus. Front. Med., 01 November 2021 | https://doi.org/10.3389/fmed.2021.737813

Abstract:

Lichen planus (LP) is a T cell-mediated...

Montag, 03.05.2021

Risk of COVID-19 in pemphigus and pemphigoid

 The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study

Kridin et al, J Am Acad Dermatol. 2021 Mar...

Mittwoch, 17.03.2021

A Mitochondrial Polymorphism Alters Immune Cell Metabolism and Protects Mice from Skin Inflammation

Abstract:

Several genetic variants in the mitochondrial genome (mtDNA), including ancient polymorphisms, are associated with chronic inflammatory conditions, but investigating the functional consequences of such mtDNA polymorphisms in humans is challenging due to the influence of many...

Mittwoch, 17.03.2021

Milestones in Personalized Medicine in Pemphigus and Pemphigoid

New paper in Front Immunol.

Abstract:

Pemphigus and pemphigoid diseases are autoimmune bullous diseases characterized and caused by autoantibodies targeting adhesion molecules in the skin and/or mucous membranes. Personalized medicine is a new medical model that separates...

Mittwoch, 17.03.2021

A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study

Abstract:

Background: Bullous pemphigoid (BP) and asthma both share a pathogenic role of eosinophils and immunoglobulin E (IgE) and favorable response for corticosteroids and omalizumab. However, the association between these conditions is yet to be...